Literature DB >> 27296298

Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC.

Josep Tabernero1, Ramon Salazar2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27296298     DOI： 10.1038/nrclinonc.2016.92

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Authors:  Guy A van Hazel; Volker Heinemann; Navesh K Sharma; Michael P N Findlay; Jens Ricke; Marc Peeters; David Perez; Bridget A Robinson; Andrew H Strickland; Tom Ferguson; Javier Rodríguez; Hendrik Kröning; Ido Wolf; Vinod Ganju; Euan Walpole; Eveline Boucher; Thomas Tichler; Einat Shacham-Shmueli; Alex Powell; Paul Eliadis; Richard Isaacs; David Price; Fred Moeslein; Julien Taieb; Geoff Bower; Val Gebski; Mark Van Buskirk; David N Cade; Kenneth Thurston; Peter Gibbs
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

2.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.

Authors:  B Gray; G Van Hazel; M Hope; M Burton; P Moroz; J Anderson; V Gebski
Journal:  Ann Oncol       Date:  2001-12       Impact factor: 32.976

3.  Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

Authors:  Alain Hendlisz; Marc Van den Eynde; Marc Peeters; Geert Maleux; Bieke Lambert; Jaarke Vannoote; Katrien De Keukeleire; Chris Verslype; Luc Defreyne; Eric Van Cutsem; Philippe Delatte; Thierry Delaunoit; Nicola Personeni; Marianne Paesmans; Jean-Luc Van Laethem; Patrick Flamen
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

4.  Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.

Authors:  Guy Van Hazel; Anthony Blackwell; James Anderson; David Price; Paul Moroz; Geoff Bower; Giuseppe Cardaci; Bruce Gray
Journal:  J Surg Oncol       Date:  2004-11-01       Impact factor: 3.454

5.  In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line.

Authors:  Johan Kjellström; Elisabeth Kjellén; Anders Johnsson
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

Review 6.  Metastatic colorectal cancer: current state and future directions.

Authors:  Marwan G Fakih
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

7.  Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.

Authors:  Ricky A Sharma; Guy A Van Hazel; Bruno Morgan; David P Berry; Keith Blanshard; David Price; Geoffrey Bower; Jennifer A Shannon; Peter Gibbs; William P Steward
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

8.  Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.

Authors:  A A Argyriou; R Velasco; C Briani; G Cavaletti; J Bruna; P Alberti; M Cacciavillani; S Lonardi; C Santos; D Cortinovis; M Cazzaniga; H P Kalofonos
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

9.  Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.

Authors:  Andrew Kennedy; Subir Nag; Riad Salem; Ravi Murthy; Alexander J McEwan; Charles Nutting; Al Benson; Joseph Espat; Jose Ignacio Bilbao; Ricky A Sharma; James P Thomas; Douglas Coldwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

10.  FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.

Authors:  Susan J Dutton; Nicola Kenealy; Sharon B Love; Harpreet S Wasan; Ricky A Sharma
Journal:  BMC Cancer       Date:  2014-07-09       Impact factor: 4.430
  10 in total
  1 in total

1.  Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.

Authors:  B Garlipp; P Gibbs; G A Van Hazel; R Jeyarajah; R C G Martin; C J Bruns; H Lang; D M Manas; G M Ettorre; F Pardo; V Donckier; C Benckert; T M van Gulik; D Goéré; M Schoen; J Pratschke; W O Bechstein; A M de la Cuesta; S Adeyemi; J Ricke; M Seidensticker
Journal:  Br J Surg       Date:  2019-08-19       Impact factor: 6.939
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.